Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Oneflow’s monthly ARR update: December 2023

Press release5 January 2024 Oneflow publishes its preliminary monthly ARR. Oneflow had a total ARR (Annual Recurring Revenue) of MSEK 129.3 by the end of December 2023. This is a preliminary number. All financial reports and presentations are available for download on our website here: https://oneflow.com/ir/investors/financial-reports/ For further information, please contact: Anders Hamnes, CEO and FounderMobile: +46 76 788 50 76Email: anders.hamnes@oneflow.com Certified Adviser is FNCA Sweden AB. About Oneflow Oneflow develops, sells, and implements digital

Finnair Traffic Performance in December 2023

Finnair Plc                Investor News              5 January 2024 at 9:00 a.m. EET Increase in passenger traffic numbers year-on-year and month-on-month, on-time performance impacted by severe weather conditions In December, Finnair carried 878,200 passengers, which was 5.4% more than in December 2022 and 8.2% more than in November 2023. Month-on-month figures are not fully comparable as there was one day less in November. December passenger traffic figures improved year-on-year as the COVID-19 pandemic impacts have mostly faded and as the Russian airspace was closed during the

Transaction in Own Shares

    05 January 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |04/01/2024|+-----------------------------------------------------------

Sobi’s Chairman of the Board resigns due to health reasons

Swedish Orphan Biovitrum AB’s (publ) (Sobi®) (STO: SOBI) (“Sobi”) Chairman of the Board Bo Jesper Hansen resigns, at his own request and with immediate effect, from his position as Chairman of the Board and board member due to health reasons.Bo Jesper Hansen has been deputy Chairman of the Board of Sobi since the annual general meeting in May 2022 and Chairman of the Board of Sobi since the annual general meeting in May 2023. Annette Clancy assumes with immediate effect the role of Chair of the Board. Annette has been a board member of Sobi since 2014 and has extensive experience from

UNION therapeutics to present at the 42nd Annual J.P. Morgan Healthcare Conference

Hellerup, Denmark, January 5, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8-11, 2024, in San Francisco, US.  Dr. Kjøller will be presenting at 11:00am PST on Monday, January 8, 2024, and will provide an update on the business with emphasis on key achievements and current status of the lead program orismilast, a potent selective PDE4 B/D inhibitor, currently in development

Stirling Square, TA and Macquarie Capital, through Giant BidCo, announce a recommended public cash offer of SEK 46 to the shareholders of Byggfakta

THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE AND IN THE

Lea bank ASA - Notice of Extraordinary General Meeting

Lea bank’s shareholders are hereby given notice of an extraordinary general meeting to be held on January 22 2024, at 10:00 AM CET (the “EGM”) at the bank's offices at Holbergs gate 21, 0166 Oslo. Please see attached notice of the EGM. The notice will be sent electronically or by mail to all shareholders with a known address. The notice and other documents related to the agenda are also available at leabank.no/about-us/investor-relations/general-meeting Contact Information: Oddbjørn Berentsen, CEO Phone: +47 22 99 14 00 Email: ir@leabank.no

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Press release Nanoform Finland Plc January 5, 2023 08:10 Finnish time / 07:10 Swedish time Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorphous solid dispersion (ASD);formulation of nanoenzalutamide and Xtandi[®[1]], the number one prescribed androgen receptor

Nordea Bank Abp: Repurchase of own shares on 04.01.2024

Nordea Bank AbpStock exchange release – Changes in company’s own shares04.01.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 04.01.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |47,051 |11.40 |536,188.49

Bioservo to be delisted from Nasdaq First North

Nasdaq has decided to approve Bioservo Technologies' application to delist its shares (short name BIOS, ISIN code SE0009779085) from Nasdaq First North Growth Market. The last day of trading on Nasdaq First North Growth Market is January 11, 2024. For more information, please contactLawyer Olov Kling, liquidator, Konrad Advokater ABphone: +46 70 210 13 79olov.kling@konradadvokater.se Mikael Wester, Marketing Director, Bioservo Technologies ABphone: +468 21 17 10mikael.wester@bioservo.com  About Bioservo TechnologiesBioservo Technologies AB (publ) is a world leading

Transaction in Own Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 04 January 2024 REDDE NORTHGATE PLC (“Redde Northgate” or the “Group” or the “Company”)   Transaction in Own Shares   Redde Northgate plc (LSE:REDD) announces that on 04 January 2024 it purchased the following number of its own shares to be held in treasury:   Class of shares :  Ordinary shares of 50p (“shares”)

#24-4 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

#24-3 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Q&A session related topline data Study 0205

On 4 January – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based all the positive feedback and questions from the release of topline data from study 0205 on 22 December 2023.1.Can the Company elaborate on the exposure data and levels in children compared to adults?A: The exposure observed in children in both the 0201 and 0206 study showed a 2 times higher exposure of both sufentanil and ketamine compared to adults in both the 0204 and 0205 studies at similar weight-adjusted dosing, highlighting that children are not just small adults.

Fodelia Oyj: Share Repurchase 4.1.2024

Fodelia Oyj Announcement  4.1.2024 Fodelia Oyj: Share Repurchase 4.1.2024 In the Helsinki Stock Exchange Trade date           4.1.2024Bourse trade         BuyShare                  FODELIAAmount             1 713 SharesAverage price/ share    5,7177 EURTotal cost            9 794,42 EUR Fodelia Oyj now holds a total of 18 781 sharesincluding the shares repurchased on 4.1.2024 On behalf of Fodelia Oyj Nordea Bank Oyj Janne Sarvikivi

Publication of Final Terms

Regulatory Announcement Publication of Final Terms NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR TO ANY PERSON OR ADDRESS IN THE U.S. EXCEPT TO QUALIFIED INSTITUTIONAL BUYERS (AS DEFINED IN RULE 144A OF THE SECURITIES ACT). Royal Bank of Canada issued USD2,000,000,000 4.851% Covered Bonds due December 14, 2026, Series CB92 on December 14, 2023 under a Pricing Supplement dated December 6, 2023 (the "Covered Bonds") pursuant to the €75,000,000,000 Global Covered Bond Programme of Royal Bank of Canada, unconditionally and irrevocably guaranteed as to payments by RBC Covered Bond

Immunovia announces financial calendar for financial year 2024

LUND, SWEDEN – Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2024.    Year-End 2023 Report February 21, 2024 Annual Report to be published March 15, 2024 Q1 Report, 2024 April 25, 2024 Q2 Report, 2024 August 22, 2024 Q3 Report, 2024 November 14, 2024   The Annual General Meeting will be held on April 25, 2024, 15:00-16:00 CET.   For more information, please contact: Karin Almqvist

Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on January 4, 2024

Today on January 4, 2024 in Gothenburg, Sweden – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extraordinary general meeting (“EGM”) at which the following principal resolutions were passed.The information in the press release is intended for investors. Election of members and chairman of the board, determination of fees to the board of directors The EGM resolved that the number of members of the board of directors shall be five without deputies. The EGM resolved that the board of directors shall consist of Jan-Eric Österlund, Lars Lind, Sten Nilsson, Helena Taflin

Veidekke: Building activity centre in Sandefjord

Veidekke has been commissioned by Sandefjord municipality to build an environmentally certified activity centre with workplaces for residents with permanent adaptation needs. This will be a design and build contract valued at close to NOK 150 million, excluding VAT.“We are very pleased that we have been awarded yet another commission for Sandefjord municipality, which is one of our most important recurring customers. The activity centre meets an important need for society, and we consider it very meaningful to build such an important building. We are therefore particularly pleased that we

ADDvise receives order worth USD 2.5 million

ADDvise Group’s subsidiary MRC Systems has received an order from SaudiVax. The company is a biotechnology company specialized in the development and production of vaccines and biopharmaceuticals. The order is worth approximately USD 2.5 million and involves design, installation, and commissioning of a cleanroom and associated accessories. The facility is located in the Kingdom of Saudi Arabia and will be used for pharmaceutical manufacturing. Delivery of the order is scheduled during 2024.  For further information, please contact: Rikard Akhtarzand, CEO+46 765-25 90 71rikard.

Audientes A/S: Minutes of Extraordinary General Meeting

Company announcement no. 01-2024 January 4, 2024     On January 4, 2024, at 15:00 CET an extraordinary general meeting was held in Audientes A/S (the “Company”, CVR-no. 36 04 76 31) at the Company’s address, Teknikerbyen 5, 2830 Virum.   The Company’s chairman Hossein Jelveh opened the meeting and informed that according to the Articles of Association section 5.6, the board of directors appointed him as chairman of the meeting.   Hossein Jelveh accepted the nomination and noted that the meeting was regularly constituted and convened and a quorum in every respect. The

There are no items matching the current filter
There are no more items matching the current filter
Back to top